AMTZ and India’s MedTech Parks: Can They Deliver the $70,000-Crore Ecosystem Promise?

Thirty kilometres from Visakhapatnam’s city centre, past the traffic and into hills near the Vizag Steel Plant, sits what has quietly become one of the largest single concentrations of medical device manufacturing anywhere in the country. Andhra Pradesh MedTech Zone — AMTZ — was built to answer a specific structural problem in Indian MedTech: no single company, however well-funded, could easily build a device from prototype to regulatory approval to manufacturing scale without infrastructure that, until AMTZ existed, simply didn’t exist domestically at all. Nearly a decade after its founding, the numbers suggest that bet has paid off further than most industrial-park experiments in India ever do — though the “Made-in-India Hospitals” ambition it’s now chasing is a considerably bigger swing.

What AMTZ Actually Is

Andhra Pradesh MedTech Zone was founded on August 19, 2016, and built in a record 342 days on 270 acres of government-owned land in the Nadupuru area of Visakhapatnam. It’s structured differently from a conventional industrial park: rather than simply leasing land and utilities to manufacturers, AMTZ built and operates shared Common Manufacturing Facilities and Common Scientific Facilities that individual device companies — especially smaller ones — could never justify building on their own. That includes a TÜV Rheinland-operated EMC and safety testing and certification facility, and a gamma irradiation sterilisation centre described as the first of its kind in Andhra Pradesh and the surrounding states, catering to roughly 15% (an estimated ₹4,500 crore) of the entire Indian medical device market’s sterilisation needs from a single location.

The philosophy is explicit: rather than functioning as a traditional industrial park that primarily provides land and infrastructure, AMTZ operates as a complete MedTech ecosystem, bringing together every stage of medical device development — research, prototyping, testing, manufacturing, certification, and commercialisation — within one integrated campus. For a sector where regulatory testing delays and fragmented supply chains have historically been among the biggest barriers to Indian device manufacturers scaling, that integration is the core value proposition.

The Numbers: 187 Manufacturers, 212 Startups, ₹70,000 Crore

As of 2026, AMTZ’s own disclosed figures put it firmly in the category of genuine scale, not aspirational branding. AMTZ CEO Dr. Jitender Sharma described it plainly at India Health 2026: AMTZ has grown into one of the world’s largest MedTech clusters, with 187 manufacturers and 212 startups generating a collective annual business of nearly ₹70,000 crore.

That figure is worth putting in context against the broader Indian medical device market. According to EY, India’s overall MedTech market is valued at around $12 billion currently, and is projected to reach $50 billion by 2030 — meaning a single manufacturing zone in Visakhapatnam is already contributing a meaningfully large slice of the entire national device manufacturing base, not a marginal fraction of it.

During the COVID-19 pandemic, AMTZ’s manufacturing capacity was tested and proven at genuine emergency scale: the zone produced over 100 ventilators, 500 oxygen concentrators, and 1 million RT-PCR kits daily during India’s pandemic response, while also dispatching mobile container hospitals, mobile RT-PCR vehicles, and mobile oxygen plants to remote parts of the country. That’s not incubator-stage output — that’s the kind of production volume that only comes from genuinely industrial-scale manufacturing infrastructure already being in place before the crisis hit.

The Startup Layer: AIC-AMTZ MediValley

Manufacturing scale is only one half of AMTZ’s model — the other is startup incubation, run through AIC-AMTZ MediValley, described as India’s largest MedTech incubator. As of its September 2025 expansion, MediValley had supported approximately 150 startups to date and was actively scaling toward a capacity of 300 ventures by 2026. That expansion was physically anchored by a new World Trade Center Tower — a 1 lakh sq. ft. facility opened in Visakhapatnam offering research labs, rapid prototyping units, testing facilities, co-working space, regulatory support, and global partnership access, all under one roof.

The incubation ecosystem isn’t purely domestic in its backing, either — it draws support from both Indian institutions (DBT-BIRAC, NITI Aayog, DPIIT, ICMR, and the Department of Pharmaceuticals) and international bodies including the WHO, the World Health Innovation Forum, and TiE — a combination explicitly designed to ensure incubated startups can access both Indian regulatory and manufacturing pathways and international market credibility simultaneously. Beyond MediValley, AMTZ’s broader specialised centres also include the Bio Valley Incubation Council, the Bharat Limb Centre (focused on prosthetics and orthotics), and a Centre of Excellence for Additive Manufacturing — spreading incubation support across several distinct MedTech sub-sectors rather than treating “startup support” as a single generic offering.

In March 2026, that capital layer got a formal boost: AMTZ partnered with MedArtha Capital to launch India’s first dedicated MedTech Capital Fund, unveiled in Mumbai by Union Commerce and Industry Minister Piyush Goyal, who described India’s MedTech sector as a “sunrise opportunity” driven by the country’s expanding talent pool and rising preventive healthcare awareness. The fund is designed to provide growth capital and strategic support specifically to emerging device companies — addressing a financing gap that has historically pushed promising Indian MedTech startups toward foreign investors or premature acquisition by larger players before they could scale domestically.

The Bigger Swing: “Made in India” Hospitals

AMTZ’s most ambitious current initiative goes well beyond manufacturing individual devices — it’s attempting to build entire hospitals using only domestically manufactured medical technology. The plan: co-create at least 100 “Made in India” hospitals, primarily across Tier-2 and Tier-3 cities, adding a combined 10,000 hospital beds nationally.

What makes this different from a typical hospital-development project is AMTZ’s role in it. Rather than acting purely as an equipment vendor, AMTZ has positioned itself as a broader facilitator across financing, construction, and equipment supply for these projects — with officials describing the concept as building an entire hospital that could be made functional and operational using exclusively Made-in-India medical equipment. If realised at anything close to the stated scale, this would be the first genuine proof point that Indian medical device manufacturing has matured enough to equip a hospital end-to-end — not just supply individual imported-alternative devices into hospitals still substantially reliant on foreign equipment for their more advanced diagnostic and surgical infrastructure.

What’s Genuinely Working

A few things about AMTZ’s model stand up to scrutiny well:

• Shared infrastructure genuinely lowers the barrier to entry for smaller manufacturers. Testing, certification, and sterilisation facilities that would be prohibitively expensive for an individual startup or MSME to build are available as shared, professionally operated infrastructure — directly addressing one of the cost barriers that has historically kept Indian MSMEs out of the more capital-intensive device categories, a gap flagged elsewhere in India’s PLI scheme rollout.
• The incubation layer has genuine scale and diversified support. 150-plus startups supported to date, scaling toward 300, backed by a mix of domestic government bodies and international health organisations, suggests a maturing pipeline rather than a one-time announcement.
• Pandemic-era production proved the manufacturing capacity is real, not aspirational. Producing over 100 ventilators and 500 oxygen concentrators daily, alongside a million RT-PCR kits, is a level of output that validates AMTZ’s manufacturing infrastructure under genuine emergency pressure — a stress test most industrial park claims never face.

What Remains Genuinely Unproven

It’s worth being equally clear-eyed about the parts of the ₹70,000-crore ecosystem promise that haven’t yet been fully delivered:

• The “Made in India” Hospitals initiative is still largely aspirational. As of the most recent reporting, AMTZ had set a plan and ambition of building 100 such hospitals, with officials suggesting India could see its first fully domestically-equipped hospital by the first half of 2026 — but achieving that at the full 100-hospital, 10,000-bed scale is a multi-year undertaking that depends on financing structures, construction timelines, and equipment availability that go well beyond what AMTZ’s existing manufacturing base has proven it can deliver.
• ₹70,000 crore in annual business across 187 manufacturers and 212 startups reflects revenue generated by companies operating within the zone, not necessarily deep, vertically-integrated component manufacturing. As with India’s broader PLI scheme experience, it’s worth asking how much of that revenue reflects genuine high-value manufacturing versus assembly of imported components — a distinction AMTZ’s own public materials don’t fully break down.
• Replicability beyond Visakhapatnam remains an open question. AMTZ is frequently described as India’s flagship medical device park, but the broader ambition of a national network of medical device parks — including sites in Uttar Pradesh, Tamil Nadu, Madhya Pradesh, and Himachal Pradesh — has developed at a considerably slower and less publicly documented pace than AMTZ itself. Whether AMTZ’s model can be genuinely replicated elsewhere, or whether it succeeded partly due to first-mover advantages and sustained state-government backing specific to Andhra Pradesh, isn’t yet clear.

The Bottom Line

AMTZ has done something genuinely uncommon in Indian industrial policy: built a piece of infrastructure that scaled from a greenfield 270-acre site in 2016 into one of the world’s largest MedTech clusters by manufacturer and startup count within a decade, with pandemic-era production numbers to back up the claim that its manufacturing capacity is real rather than theoretical. The ₹70,000 crore annual business figure and the growing MediValley incubation pipeline are legitimate achievements worth taking seriously.

The “Made-in-India Hospitals” ambition is the much harder next test — a bet that Indian device manufacturing has matured enough, across enough categories simultaneously, to equip entire hospitals rather than just supplying individual products into facilities still substantially dependent on imports for their most advanced equipment. Whether AMTZ delivers on that promise at genuine scale, or whether it remains a strong regional manufacturing success story that hasn’t yet cracked the harder problem of comprehensive import substitution, is the question the next two to three years will answer.

References

1. BioSpectrum India — Rs 70,000 Cr MedTech Ecosystem Takes Centre-Stage at India Health 2026 (https://www.biospectrumindia.com/news/16/28355/rs-70000-cr-medtech-ecosystem-takes-centre-stage-at-india-health-2026.html)
2. Towards Healthcare — AMTZ Expands with New World Trade Center Tower to Power MedTech Startups in India (https://www.towardshealthcare.com/news/amtz-medtech-innovation-expansion-india)
3. Business Standard — From Vizag’s Fringes, AMTZ Prescribes Fully ‘Made in India’ Hospitals (https://www.business-standard.com/industry/news/from-vizag-s-fringes-amtz-prescribes-fully-made-in-india-hospitals-125111901060_1.html)
4. AMTZ — Official Website (https://amtz.in/)
5. Wikipedia — Andhra Pradesh MedTech Zone (https://en.wikipedia.org/wiki/Andhra_Pradesh_Medtech_Zone)
6. The Hans India — AMTZ: India’s Most Comprehensive MedTech Innovation Ecosystem (https://www.thehansindia.com/news/cities/visakhapatnam/amtz-indias-most-comprehensive-medtech-innovation-ecosystem-1101756)
7. Medical Buyer — AMTZ, Vizag Emerges as India’s Comprehensive MedTech Innovation Ecosystem (https://medicalbuyer.co.in/amtz-vizag-emerges-as-indias-comprehensive-medtech-innovation-ecosystem/)
8. MedGate Today — India’s First Fund For MedTech Launched (https://medgatetoday.com/indias-first-fund-for-medtech-launched/)

Note: Figures on manufacturer/startup counts, revenue, and expansion timelines reflect AMTZ’s own public statements and press coverage current as of mid-to-late 2026. The “Made in India Hospitals” initiative remained in planning and early execution stages at the time of writing; actual delivery timelines and final scale may differ from stated targets.